Optical Coherence Tomography to visualize neuropathology in Alzheimer's disease

Optical Coherence Tomography to visualize neuropathology in Alzheimer's disease - OCT in AD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45755

Enrollment

120

Registered

2016-10-18

Start date

2016-10-25

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease and dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Study cases: patients with AD fulfilling the clinical criteria, a MMSE-score of at least 17/30 and proven to be amyloid positive by either decreased CSF A* or a positive amyloid PET scan. - Controls: patients with subjective memory complaints visiting the Alzheimer center, without diagnosis of AD or other neurodegenerative disease, proven to be amyloid negative by either normal CSF A* or negative amyloid PET scan.

Exclusion criteria

Exclusion criteria: - Subjects with neuro-opthalmological conditions which may interfere with the OCT data - Subjects with progressive dementia, with an MMSE below 17/30 and/or incapacitated and not capable to give informed consent.

Design outcomes

Primary

Measure	Time frame
- OCT: thickness of the individual retinal layers, including the choroid, at the macular region and optic disc - PS-OCT: presence (and number) of amyloid plaques, thickness and change in birefringence of RNFL - Angio-OCT: changes in vessel density around the optic nerve head	—

Secondary

Measure	Time frame
- Relate the amount of visualized A*-plaques in the retina of AD patients to other available AD biomarkers (i.e. hippocampal atrophy, CSF biomarkers and amyloid PET scan). - Compare findings of standard OCT with available biomarkers (i.e. hippocampal atrophy, CSF biomarkers and amyloid PET scan) - Compare findings in vessel density around the optic nerve head to existing vascular markers (scores on MRI)	—

Measure

Time frame

- Relate the amount of visualized A*-plaques in the retina of AD patients to other available AD biomarkers (i.e. hippocampal atrophy, CSF biomarkers and amyloid PET scan). - Compare findings of standard OCT with available biomarkers (i.e. hippocampal atrophy, CSF biomarkers and amyloid PET scan) - Compare findings in vessel density around the optic nerve head to existing vascular markers (scores on MRI)

—

Countries

Netherlands

Outcome results